Glucose dysregulation associated with antidepressant agents: an analysis of 17 published case reports

Abstract

It is not clear from published case reports whether changes in glucose regulation, following antidepressant therapy initiation are due to antidepressants or changes in mood and lifestyle. Nonetheless, healthcare providers should be aware of the potential changes in glucose regulation especially in the first month of antidepressant therapy, and use appropriate clinical and laboratory monitoring to prevent serious adverse events in patients at risk.

The Prevalence of Metabolic Syndrome In Chronic Obstructive Pulmonary Disease: A Systematic Review

“…Indeed, of the four studies in COPD reporting medication use, two found a significantly higher use of steroids in the group with MetS (28,31). Other common medications in COPD, such as anti-depressants can cause impaired glucose tolerance (48), further contributing to MetS. Medications can thus influence MetS prevalence in COPD and need to be considered in future studies.…”

Fluoxetine Impairs Insulin Secretion without Modifying Extracellular Serotonin Levels in MIN6 β-cells

“…A meta-analysis showed that short period of fluoxetine therapy can lead to weight loss as well as reduction of fasting plasma glucose, HbA1c and triglyceride in T2D [25]. However, another meta-analysis only concluded that "is not clear whether changes in glucose regulation, following antidepressant therapy are due to antidepressants or changes in mood and lifestyle" [26]. One possible explanation for the discordant effect of SSRIs on human glucose homeostasis, might be based on a double mechanism of adverse effects: on one hand, the inhibitory effects in GSIS on β-cells and, on the other hand, its possible positive effect on insulin sensitivity.…”

Diagnosis and management of glycogen storage disease type I: a practice guideline of the American College of Medical Genetics and Genomics

“…Insulin and insulin secretagogues (sulfonylureas) should be used with caution. 164,165 Growth hormone treatment should also be avoided because it can result in the development or an increase in the size or number of liver adenomas, along with severe hyperlipidemia. The use of growth hormone should clearly be limited to only those who are proven to have a growth hormone deficiency and, in this situation, close monitoring for liver adenomas and metabolic disturbances is critical.…”